Document is current
Any future updates will be listed below
-
Authors
Everette, Kelcee A. https://orcid.org/0000-0003-4421-971X
Newby, Gregory A. https://orcid.org/0000-0001-7869-2615
Levine, Rachel M. https://orcid.org/0000-0002-3684-2950
Mayberry, Kalin
Jang, Yoonjeong
Mayuranathan, Thiyagaraj https://orcid.org/0000-0002-9505-0363
Nimmagadda, Nikitha https://orcid.org/0000-0003-1648-6335
Dempsey, Erin
Li, Yichao
Bhoopalan, Senthil Velan https://orcid.org/0000-0002-1402-6549
Liu, Xiong
Davis, Jessie R.
Nelson, Andrew T.
Chen, Peter J.
Sousa, Alexander A.
Cheng, Yong https://orcid.org/0000-0002-9314-0971
Tisdale, John F.
Weiss, Mitchell J. https://orcid.org/0000-0002-6734-4858
Yen, Jonathan S. https://orcid.org/0000-0002-9432-9450
Liu, David R. https://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01 AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL156647, R01 HL136135)
Bill and Melinda Gates Foundation
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 3 January 2023
Accepted: 22 March 2023
First Online: 17 April 2023
Change Date: 15 May 2023
Change Type: Update
Change Details: In the version of this article initially published, an incorrect version of the Reporting Summary was posted, which is now updated in the HTML and PDF versions of the article.
Competing interests
: The authors have filed patent applications on prime editing through the Broad Institute (Cambridge, MA). D.R.L. is a consultant and equity owner of Prime Medicine, Beam Therapeutics, Pairwise Plants, Nvelop Therapeutics and Chroma Medicine, companies that use or deliver genome editing or epigenome-modulating agents. M.J.W. is a consultant for GSK plc, Cellarity Inc., Novartis and Dyne Therapeutics. J.S.Y is an equity owner of Beam Therapeutics. J.R.D. and P.J.C. are currently employees of Prime Medicine. The other authors declare no competing interests.
